ReviewDiagnostic histopathology (Oxford, England)2021
Histopathology features of the lung in COVID-19 patients.
Review in Diagnostic histopathology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Natural SARS-CoV-2 infection in farmed minksFrontiers in veterinary science · 2026Article
- Lung long distance: histopathological changes in lung tissue after COVID-19 pneumonia.Croatian medical journal · 2024Article
- Mexican Hispanics show significant improvement in lung function approximately 1 year after having severe COVID-19.Experimental physiology · 2024Observational
- A Histological Analysis and Detection of Complement Regulatory Protein CD55 in SARS-CoV-2 Infected Lungs.Life (Basel, Switzerland) · 2024Article
- Immunohistochemical and Morphometric Analysis of Lung Tissue in Fatal COVID-19.Diagnostics (Basel, Switzerland) · 2024Article
- Article
- Single cell spatial analysis reveals inflammatory foci of immature neutrophil and CD8 T cells in COVID-19 lungs.Nature communications · 2023Article
- Virulence Profiles of Wild-Type, P.1 and Delta SARS-CoV-2 Variants in K18-hACE2 Transgenic Mice.Viruses · 2023Article
- Morphological and functional findings in COVID-19 lung disease as compared to Pneumonia, ARDS, and High-Altitude Pulmonary Edema.Respiratory physiology & neurobiology · 2023Review
- New and personalized ventilatory strategies in patients with COVID-19.Frontiers in medicine · 2023Review
- SARS-CoV-2 infection downregulates myocardial ACE2 and potentiates cardiac inflammation in humans and hamsters.American journal of physiology. Heart and circulatory physiology · 2022Article
- COVID-19 and fibrosis: Mechanisms, clinical relevance, and future perspectives.Drug discovery today · 2022Review
- Blocking Toll-like receptor 9 attenuates bleomycin-induced pulmonary injury.Journal of pathology and translational medicine · 2022Article
- Persistent SARS-CoV-2 antigen presence in multiple organs of a naturally infected cat from Brazil.The journal of venomous animals and toxins including tropical diseases · 2022Article
- Article
- COVID-19 post-mortem findings: how the departed can teach us.Diagnostic histopathology (Oxford, England) · 2021Article
- Clinical manifestations and socio-demographic status of COVID-19 patients during the second-wave of pandemic: A Bangladeshi experience.Journal of infection and public health · 2021Article
- Severe acute respiratory syndrome-coronavirus 2 in domesticated animals and its potential of transmission: A meta-analysis.Veterinary world · 2021Article
- Human Coronaviruses: Counteracting the Damage by Storm.Viruses · 2021Review
- The Role of Alveolar Edema in COVID-19.Cells · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is the infectious disease caused by the recently discovered coronavirus, SARS-CoV-2, unknown before the outbreak in Wuhan, China, in December 2019. COVID-19 is a pandemic, infectious disease that has simultaneously affected many countries globally. The leading cause of dead in patients with COVID-19 is hypoxic respiratory failure from acute respiratory distress syndrome (ARDS). Diffuse alveolar damage (DAD) is the histopathological pattern commonly described in all the postmortem series up to date. DAD is divided into two phases, and depending on the length of the disease, the morphological features seen in the specimens vary. There is an acute/exudative phase, which occurs during the first week after the pulmonary injury, following by the organizing/proliferative phase. Additional features detailed include vascular thrombosis, endothelialitis and angiogenesis. Interestingly, there is an ongoing discussion about the specificity of these changes, as diffuse alveolar damage seen in other viral infections show similar features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.